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BACKGROUND: The aim of this study was to investigate the prognostic effect of tumour-infiltrating lymphocytes (TILs) in serous stage III
ovarian carcinoma to determine TIL clonality and to correlate this to Her2/neu expression.
METHODS: Formalin-fixed and paraffin-embedded ovarian carcinomas were examined for CD20-, CD3-, CD4- and CD8-positive
lymphocytes (n¼100), and for Her2/neu-positive tumour cells (n¼55/100) by immunohistochemistry. Clonality analysis was carried
out by T-cell receptor g (TCRg) gene rearrangements (n¼93/100). Statistical analyses included experimental and clinico-pathological
variables, as well as disease-free (DFS) and overall (OS) survival.
RESULTS: CD20-positive B lymphocytes were present in 57.7% (stromal)/33.0% (intraepithelial) and CD3-positive T lymphocytes in
99.0% (stromal)/90.2% (intraepithelial) of ovarian carcinomas. Intraepithelial CD3-positive T lymphocytes were correlated with
improved DFS in optimally debulked patients (P¼0.0402). Intraepithelial CD8-positive T lymphocytes were correlated with
improved OS in all optimally debulked patients (P¼0.0201) and in those undergoing paclitaxel/carboplatin therapy (P¼0.0092).
Finally, rarified and clonal TCRg gene rearrangements were detected in 37 out of 93 (39.8%) and 15 out of 93 (16.1%) cases,
respectively. This was marginally associated with improved DFS (P¼0.0873). Despite a significant correlation of HER2/neu status and
intraepithelial CD8-positive lymphocytes (P¼0.0264), this was non-directional (R¼ 0.257; P¼0.0626).
CONCLUSION: Improved survival of ovarian cancer patients is related to the infiltration, clonal selection and intraepithelial persistence of
T lymphocytes.
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Ovarian cancer is the leading cause of death from gynaecological
cancers, and the fifth leading cause of cancer death in women
(Runnebaum and Stickeler, 2001; Jemal et al, 2005). The majority
(90%) of primary ovarian tumours derives from epithelial cells, the
remainder arise from other cell types (e.g., germ cell tumours, sex
cord-stromal tumours and mixed cell tumours) (Scott and
McCluggage, 2006). As symptoms of early-stage disease are vague,
and as valid markers for early-stage ovarian cancer are still
missing, most patients are diagnosed in advanced stages (Inter-
national Federation of Gynecology and Obstetrics (FIGO) stages III
and IV) (Bhoola and Hoskins, 2006). The associated 5-year
survival rate for advanced ovarian cancer is only 30–40%
(Runnebaum and Stickeler, 2001; Pfisterer et al, 2005). Standard
treatment involves surgical resection of the tumour with the goal of
complete tumour reduction (optimal debulking) (Pfisterer et al,
2005) and adjuvant chemotherapy, with a standard combination of
a taxane (e.g., paclitaxel and docetaxel) and a platinum (e.g.,
carboplatin and cisplatin) compound (du Bois et al, 2005; Bhoola
and Hoskins, 2006). Established prognostic factors are stage,
histologic subtype, tumour grade, the debulking status of the
primary surgical resection and response to chemotherapy, which is
measured in terms of disease-free survival (DFS) (Jemal et al, 2005;
Bhoola and Hoskins, 2006). Reliable outcome prediction for DFS
and overall survival (OS), however, still remains difficult, even for
patients with similar clinico-pathological characteristics, and the
search for valid clinical and/or molecular markers for prognosis
and prediction of therapeutic response is ongoing.
Infiltration by immune cells (tumour-infiltrating lymphocytes
(TILs)) is a central mechanism of the ‘hosts’ response to several
types of human carcinomas and the TIL-mediated activity may be
directed against tumour cell antigens (Parmiani, 2005). TILs have
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sbeen recognised in several major human cancers, such
as in adenocarcinomas of the lung (Dieu-Nosjean et al,
2008), the colorectum (Galon et al, 2006) and the breast
(Sheu et al, 2008).
In the case of ovarian cancer (Zhang et al, 2003; Curiel et al,
2004; Raspollini et al, 2005; Sato et al, 2005; Hamanishi et al, 2007;
Tomsova ´ et al, 2008; Clarke et al, 2009; Leffers et al, 2009),
the presence of T-lymphocyte infiltration in ovarian carcinomas
has a major impact on the progression and clinical follow-up
of patients. In particular, it has been shown that high numbers of
CD3-positive T cells are indicative of improved survival
(Zhang et al, 2003; Raspollini et al, 2005; Tomsova ´ et al, 2008)
and that the CD8-positive (cytotoxic) subtype of CD3-positive T
lymphocytes is responsible for this effect (Sato et al, 2005;
Hamanishi et al, 2007; Clarke et al, 2009; Leffers et al, 2009). In
contrast, the presence of the CD4-positive regulatory subtype of T
lymphocytes (Treg; CD4þCD25þFoxP3þ) seems to reduce
tumour-specific immunity and results in a poorer survival of
patients with ovarian carcinomas (Curiel et al, 2004). Moreover,
the exact location of TILs within the tumour mass has been shown
to be important for the prognostic effect in ovarian cancer (Zhang
et al, 2003; Sato et al, 2005; Clarke et al, 2009). As observed for
colorectal cancers (Galon et al, 2006), ‘intratumoural’ infiltration
by TILs is considered to be essential for revealing a prognostic
impact.
Despite this wealth of information on TIL in ovarian carcinomas,
several issues remain unclear. In particular, this applies to the
definition and clinical impact of both ‘intra’- and ‘extra’-tumoural
TILs for ovarian carcinoma patients treated with different adjuvant
chemotherapy protocols. Moreover, the mechanism of TIL
function within the tumour parenchyma requires further investi-
gation. It may well be that ‘intratumoural’ TILs require recognition
of tumour-specific antigens to become (re-)activated and persis-
tent within the tumour parenchyma, as only then will they gain the
ability to stimulate an anti-tumoural response. Clearly, if single
tumour-cell-specific antigens are responsible for triggering this
activation of TILs and the subsequent anti-tumoural responses, the
activated TILs may be clonally restricted. This scenario has been
proposed and experimentally supported in the case of HER2/neu-
expressing tumour cells in breast carcinomas (Peoples et al, 1995;
Wiech et al, 2008, Goodell et al, 2008). Evidence of such a
mechanism for TILs in ovarian carcinoma is still sparse (Raspollini
et al, 2005; Yang et al, 2007), especially as the rate of HER2/neu-
expressing tumour cells varies from 1.9 to 35% (Press et al, 2005).
Nevertheless, the identification of clonally restricted TILs repre-
sents an important basis for further exploitation and development
of immune-based therapies (Sabbatini and Odunsi, 2007), also
targeting Her2/neu (Disis et al, 2002). Although the identification
of the target antigen (or antigens) recognised by prognostically
beneficial TILs is highly complex, the specifically (re-)activated
and hence clonal TILs can be examined by the determination of
T-cell receptor (TCR) gene rearrangements. Similar approaches are
used routinely for the molecularpathological analysis of suspected
malignant lymphomas (van Dongen et al, 2003).
The aim of this study was to characterise the presence and exact
localisation of TILs by immunohistochemistry in a homogeneous
group of 100 serous FIGO stage III ovarian carcinoma patients treated
by different adjuvant chemotherapy protocols. This allowed us to
further examine and validate the prognostic value of stromal and
intraepithelial TILs in clinically relevant sub-groups of ovarian
carcinoma patients. Moreover, we analysed TCR chain rearrange-
ments and Her2/neu expression to determine whether the generally
accepted prognostic benefit of T lymphocytes in ovarian carcinomas
(Zhang et al, 2003; Curiel et al, 2004; Raspollini et al, 2005; Sato et al,
2005; Hamanishi et al, 2007; Tomsova ´ et al, 2008; Clarke et al,2 0 0 9 ;
Leffers et al, 2009) is caused by a specific (re-)activation of individual
clonally restricted TILs within the tumour parenchyma by HER2/neu-
expressing tumour cells.
MATERIALS AND METHODS
Patients and tissues
The study included tissue specimens of 100 Caucasian patients
with FIGO stage III serous ovarian carcinomas, treated between
1998 and 2005 at the Department of Obstetrics and Gynecology,
University Hospital of Freiburg. The median clinical follow-up of
patients was 22.5 months (range 1–82 months) and the major
clinico-pathological data are given in Table 1. The terms ‘disease-
free survival’ and ‘overall survival’ denote the time from the
primary resection of ovarian carcinoma until the events of tumour
recurrence and death due to ovarian cancer, respectively.
Formalin-fixed and paraffin-embedded tissue specimens of all
cases were derived from routinely processed primary resection
specimens (archive, Institute of Pathology, University Medical
Center, Freiburg, Germany). Only tissue specimens of the central
areas of ovarian carcinomas, that is, excluding metastases,
were used. In addition, tissue specimens of 24 non-neoplastic,
uninvolved ovaries from patients undergoing surgery for other
purposes (for example, cysts) were included as normal controls.
This study was approved by the local ethics committee (#97/05;
Ethik-Kommission der Albert-Ludwigs-Universita ¨t, Freiburg,
Germany). Routinely processed haematoxylin and eosin-stained
tissue sections of invasive carcinomas were re-evaluated according
to WHO (Tavassoli and Deville, 2003) and UICC (Sobin and
Wittekind, 2002) classifications, and representative tissue areas of
invasive carcinomas, reflecting about 60% tumour and 40% stroma
content, were selected for the construction of tissue microarrays
(TMAs) with core biopsies of 0.2cm diameter.
Table 1 Clinico-pathological parameters of investigated ovarian carcinomas
n %
Patient age (years) 64 (32–85)
FIGO stage
IIIB 4 4
IIIC 96 96
Tumour histology
Serous 100 100
Tumour grading
11 1
23 1 3 1
36 6 6 6
42 2
Debulking status
41cm 25 26
o1cm 72 74
Adjuvant therapy
None 7 7
Paclitaxel/carboplatin 60 62
Other 30 31
Clinical follow-up
Incidence of recurrence 52/77 (68%)
Disease-free survival (median months) 15 (range 1–53)
Incidence of death 55/97 (57%)
Overall survival (median months) 19 (range 1–82)
All patients were Caucasians and had not received any immunotherapy and/or HER2-
targeted therapy. The term ‘disease-free survival’ and ‘overall survival’ denote the
time from the primary resection of the ovarian carcinoma until the events of tumour
recurrence and death due to ovarian cancer, respectively.
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sImmunohistochemistry
For immunohistochemical analysis, serial sections of TMAs were
cut at 3-mm thickness, deparaffinised in xylene, graded alcohol
(2 100; 95, 75, 50%) and water, and were subsequently subjected
to antigen retrieval in Tris-EDTA-buffered or citrate-buffered
solutions in a pressure cooker, according to routine protocols for
the selected antibodies (CD20: pH 9.0, CD3: pH 9.0, CD4: pH 9.9,
CD8: pH 6.0 and Her2/neu: pH 6.0). This was followed by
routine staining on a DAKO Autostainer with primary antibodies
(all from DAKOCytomation, with final dilution of CD20¼1:200;
CD3¼1:200; CD4¼1:500; CD8¼1:200 and Her2/neu¼1:350)
for 60min and by a secondary antibody incubation and detection
using the LSAB-Fast red system (DakoCytomation, Glostrup,
Denmark). Sections of formalin-fixed and paraffin-embedded
normal tonsils and a breast cancer sample were run in parallel
as positive controls.
In the ovarian carcinoma samples, scoring of CD20, CD3, CD4
and CD8 protein expression was carried out separately for
intraepithelial and stromal (tumour-associated stroma and/or
perivascular spaces) tumour areas (each three high-power fields
(HPF) at  40 magnification), with scores adapted from Zhang
et al (2003): Score 0¼no staining; score 1¼fewer than five
positive lymphocytes per HPF; score 2¼5–20 positive lympho-
cytes per HPF and score 3¼more than 20 positive lymphocytes
per HPF. The evaluation of Her2/neu staining in invasive tumour
cells was carried out according to routine diagnostic guidelines,
with score 0¼negative Her2/neu expression or incomplete
membranous Her2/neu expression in o10% of invasive tumour
cells; score 1¼partial membranous Her2/neu expression in 410%
of invasive tumour cells; score 2¼weak, but complete membra-
nous Her2/neu expression in 430% of invasive tumour cells and
score 3¼strong and complete membranous Her2/neu expression
in 430% of invasive tumour cells.
In non-neoplastic ovaries, the same CD scoring system was
applied for analysing the presence of lymphocytes (score 1–3) in
three randomly chosen HPFs within the entire tissue section.
Analysis of TCR c gene rearrangements
For evaluation of T-cell clonality, each two 10-mm serial sections of
invasive ovarian cancers (n¼100) and non-neoplastic ovaries
(n¼24) were subjected to deparaffination in xylene, graded
alcohol (2  100; 95, 75, 50%) and water, followed by a brief
staining in instant haematoxylin (Shandon, Thermo Scientific,
Oberhausen, Germany). Using fine needles, invasive tumour cells
(ovarian cancers) or ovarian stromal cells (non-neoplastic ovaries)
were microdissected under a stereotactic microscope (Zeiss,
Carl Zeiss, Go ¨ttingen, Germany) and subjected to DNA extraction
according to protocols of the DNeasy Kit (Qiagen). DNA was
eluted in a 100ml elution buffer and each 10ml DNA was used for
PCR-based analysis of the TCR Vg1-8,10 (tube A) and Vg9,11 (tube
B) chains using a modified protocol of Biomed-2 PCR and capillary
electrophoresis analysis (van Dongen et al, 2003). In brief, for tube
A1 0ml of DNA was mixed with 25.5ml water, 5ml of 2.5mM dNTPs,
5mlo f2 0m M MgCl2 PCR buffer, 0.5ml of AmpliTaq Gold (Applied
Biosystems, Darmstadt, Germany) and 1ml each of primers Vg1f,
Vg10, Jg1.1/2.1 and FAM-labelled Jg1.3/2.3. For tube B, 10mlo f
DNA was mixed with the same reagents, but with different primers:
1ml each of Vg9, Vg11, Jg1.1/2.1 and FAM-labelled Jg1.3/2.3. The
PCR reactions were run on a PTC200 thermal cycler (MJResearch/
Biozym, Hess. Oldendorf, Germany) using the following protocol:
denaturation at 941C for 7min, followed by 40 cycles of (1) 941C
for 1min, (2) 601C for 1min and (3) 721C for 1min, and a final
extension step of 721C for 7min. The PCR products were analysed
together with a differentially labelled size standard on a Applied
Biosystems 3100XL Genetic analyser (Applied Biosystems) and the
resulting capillary electropherogram traces were evaluated for the
occurrence of distinct multiple (rarified) or single (clonal) peaks in
the range of 150–250 base pairs (tube A products) and 110–210
base pairs (tube B products) (van Dongen et al, 2003). For
statistical analyses, cases were separated into those with polyclonal
TCR Vg gene rearrangements, and those with rarified and/or clonal
TCR Vg gene rearrangements.
Statistical evaluation
Correlations between parameters were determined using the
Pearson’s correlation coefficient. The ANOVA, t-test or Mann–
Whitney test were applied to compare all continuous parameters
either for different classes or for two-class cases. Frequency tables
were tested by the w
2-test for the comparison of discrete
parameters. Stepwise Cox-regression analysis was used to test
the significance of parameters with survival time or DFS time
(Maximum Likelihood estimates, Wald and w
2-test). For discrete
parameters, Kaplan–Meier curves for different strata were plotted
for DFS and OS. The log-rank test was used to test the significance
of two survival curves. The tests were two-sided and P-values
o0.05 were considered to be statistically significant and are
referred to as ‘correlation’, whereas P-values of 0.05–0.1 are
considered as ‘trend’ and termed as ‘trend of a correlation’. All
statistical evaluations were carried out using statistical program
package SAS (SAS Institute, Inc. Cary; NC, USA).
RESULTS
Characterisation of lymphocyte infiltration in ovarian
cancers
Immunohistochemical staining and evaluation were successful for
CD20 in 97 out of 100 (97%) cases, for CD3 in 92 out of 100 (92%)
cases, for CD4 in 86 out of 100 (86%) cases and for CD8 in 97 out
of 100 (97%) cases. A complete or partial loss of tumour area after
the staining procedure of TMAs was responsible for the failure of
evaluation in some samples. Figure 1 provides a summary of the
evaluated lymphocyte infiltration in non-neoplastic ovaries, and
for stromal and intraepithelial tumour areas in ovarian carcino-
mas. Representative photographs of immunohistochemical stain-
ings are given in Figure 2.
In non-neoplastic ovaries, CD20-, CD3-, CD4- and CD8-positive
lymphocytes were present at low numbers in 47.8, 90.5, 44.4 and
66.7% of cases, respectively.
In ovarian carcinomas, stromal CD20-, CD3-, CD4- and CD8-
positive lymphocytes were detected in 57.7, 99.0, 96.4 and 91.7% of
cases and intraepithelial CD20-, CD3-, CD4- and CD8-positive
lymphocytes were detected in 33.0, 90.2, 74.4 and 81.4% of cases,
respectively. In contrast to non-neoplastic ovaries, ovarian
carcinomas were predominantly infiltrated by higher numbers of
lymphocytes. Statistical comparison of lymphocyte subsets be-
tween non-neoplastic ovaries and either stromal or intraepithelial
ovarian carcinomas revealed significantly elevated CD3 (Po0.001),
CD4 (P¼0.002) and CD8 (Po0.001) positive stromal lymphocytes
or significantly elevated CD20 (P¼0.001), CD3 (Po0.001), CD4
(Po0.001) and CD8 (Po0.001) positive intraepithelial lympho-
cytes in ovarian carcinomas. There was no difference between the
presence of CD20-positive lymphocytes in non-neoplastic ovaries
and stromal tumour areas (P¼0.136).
Lymphocyte infiltration influences the survival of ovarian
carcinoma patients
To evaluate whether the presence of lymphocytes is of prognostic
value, statistical analyses (Figure 3) were performed with respect to
DFS and OS within all stage III patients (n¼100), in stage III
patients with optimal debulking (n¼72), as well as in stage III
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paclitaxel/carboplatin therapy (n¼43).
Using the log-rank test to determine the significance of
lymphocyte infiltration for survival, only stromal (P¼0.0534)
and intraepithelial (P¼0.0402) CD3-positive T cells showed a
trend and significant correlation with DFS for stage III patients
with optimal debulking, respectively.
However, as this did not reflect the increasing numbers of T cells
being linked to increasingly better survival, we performed an
additional Cox-regression analysis. This analysis revealed a
significant prognostic impact of increasing CD8-positive lympho-
cyte infiltration in long-term OS, that is, the effect only becoming
apparent after a lag phase of about 1 year after surgery (Figure 3).
Importantly, increasing numbers of intraepithelial CD8-positive T
lymphocytes were significantly associated with increasingly
improved OS 15 months after surgery for all optimally debulked
stage III patients (P¼0.0201), as well as for optimally debulked
stage III patients who had received adjuvant paclitaxel/carboplatin
chemotherapy (P¼0.0092) (Figure 3A and B). In contrast, stromal
CD8-positive T lymphocytes had no influence on OS in these
patient sub-groups (all optimally debulked stage III patients:
P¼0.0978; optimally debulked stage III patients having received
paclitaxel/carboplatin therapy: P¼0.3574; Figure 3C and D).
Finally, multivariate stepwise Cox-regression analysis for OS,
with all clinico-pathological and experimental parameters, vali-
dated debulking surgery (Po0.0001; hazard ratio (HR)¼0.231;
95% confidence¼0.116–0.462) and type of adjuvant chemother-
apy (P¼0.0014; HR¼2.923; 95% confidence¼1.513–5.648), as
well as intraepithelial infiltration of CD8-positive T lymphocytes
(P¼0.0005; HR¼0.408; 95% confidence¼0.246–0.678) as sig-
nificant prognostic factors. In this, optimal debulking surgery,
adjuvant paclitaxel/carboplatin therapy and high numbers of
intraepithelial CD8-positive T lymphocytes were significantly
associated with improved survival.
Analysis of TCRc gene rearrangements
To assess whether TILs in ovarian carcinomas carried clonal TCR
gene rearrangements, thereby indicating a potential recognition of
a specific tumour cell antigen, we analysed TCRg genes using the
Biomed-2 protocol (van Dongen et al, 2003). Appropriate DNA
and PCR quality was obtained from 93 out of 100 (93%) ovarian
carcinomas and from 19 out of 24 (79%) non-neoplastic ovaries.
In non-neoplastic ovaries, we observed poly- and ‘oligoclonal’,
that is, ‘rarified’ as compared with typical polyclonal, TCRg gene
rearrangements in 10 out of 19 (52.6%; Vg1-8,10) and 9 out of 19
(47.4%; Vg9,11) cases (Figure 4A). As only low numbers of T
lymphocytes had been detected (Figure 1) in these non-neoplastic
ovaries, the oligoclonal pattern might simply reflect ‘pseudoclon-
ality’, that is, the detection of single or few T lymphocytes not
related to an antigen-specific response.
In ovarian carcinomas of stage III patients (n¼93), polyclonal TCRg
gene rearrangements were observed in 41 out of 93 (44.1%) cases,
rarified TCRg gene rearrangements in 37 out of 93 (39.8%) cases and
clonal TCRg gene rearrangements in 15 out of 93 (16.1%) cases
(Figure 4A). Clonal TCRg gene rearrangements were detected for Vg1-8
or Vg10 chains in 6 out of 93 (6.5%) cases and for Vg9o rV g11 chains
in 9 out of 93 (9.7%) cases. Finally, there was a trend of a correlation of
rarified/clonal TCRg gene rearrangements with improved DFS
(P¼0.0873), but not OS, (P¼0.3177) in patients with stage III ovarian
carcinomas and optimal debulking surgery (Figure 4B).
Investigation of Her2/neu expression, TILs and TCRc
restriction in ovarian carcinomas
The Her2/neu protein expression has been associated with clonal T
lymphocytes in breast cancer patients (Peoples et al, 1995; Goodell
et al, 2008; Wiech et al, 2008), and strategies of immunotherapy
eliciting antibody and CD8-positive T-cell responses against Her2/
neu are being discussed (Disis et al, 2002). Therefore, we next
investigated the Her2/neu protein expression in a subset of
patients.
A positive Her2/neu protein expression was found in 37 out
of 55 (67.2%) cases, with a Her2/neu score of 2 in 12 out of 55
(21.8%) and a score of 3 in 3 out of 55 (5.5%) cases. In this series
of cases, the Her2/neu expression did not have any prognostic
value in the different sub-groups of patients studied. Moreover,
Her2/neu expression was linked to intraepithelial (P¼0.0264), but
not stromal (P¼0.1418), CD8-positive T-lymphocyte infil-
tration. Intriguingly, this correlation was non-directional, and
increasing Her2/neu scores were marginally associated with lower
numbers of intraepithelial CD8-positive T-lymphocyte infiltration
(R¼ 0.257; P¼0.0626). There was also no significant correlation
of HER2 expression with TCRg restriction (P¼0.7245).
DISCUSSION
In this study, we further clarified and validated the prognostic
significance of TILs in ovarian carcinoma, by focussing on the
exact location of TILs within the tumour mass, in a homogeneous
group of serous stage III ovarian carcinoma patients and the
clinically important sub-groups of optimally debulked and
paclitaxel/carboplatin-treated patients. Furthermore, we provide
data supporting the concept that the presence and persistence of
lymphocytes within ovarian carcinomas may be triggered by clonal
selection and/or restriction of T lymphocytes against specific
(tumour cell) antigens. We conclude that such T lymphocytes
infiltrating and persisting in the tumour parenchyma may be
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Figure 1 Summary of lymphocyte infiltration in ovarian carcinomas. The
graphs provide the distribution of immunohistochemical scores, that is,
lymphocyte infiltration (given as the percentage of cases with each IHC
score on the y axis; Materials and Methods) in non-neoplastic ovaries (A),
as well as for stromal (B) and intraepithelial lymphocytes infiltration (C)i n
ovarian carcinomas. Note the increased presence of CD3-positive as
compared with CD4- and CD8-positive T lymphocytes in ovarian
carcinomas (shift of bars to right; refer to text for P-values).
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for the further development of immune-mediated therapy.
In the past decade, several investigators have recognised the
immune system and, in particular, the presence of TILs as a
valuable, clinically relevant prognostic marker and as an
immunological basis for the development of novel therapeutic
strategies in patients with epithelial cancers (Parmiani, 2005) such
as adenocarcinomas of the lung (Dieu-Nosjean et al, 2008), the
colorectum (Galon et al, 2006) and the breast (Sheu et al, 2008).
In the case of ovarian carcinomas, TILs have been characterised
and further specified in functional terms in a variety of studies,
and the general consensus is that the presence of T lymphocytes
has a major impact on the progression and clinical course of the
disease. In particular, it was shown that high numbers of CD3-
positive T cells are indicative for improved survival (Zhang et al,
2003; Curiel et al, 2004; Raspollini et al, 2005; Sato et al, 2005;
Hamanishi et al, 2007; Tomsova ´ et al, 2008; Clarke et al, 2009;
Leffers et al, 2009) and that this effect is mediated preferentially by
the CD8-positive (cytotoxic) subtype of CD3-positive T lympho-
cytes (Sato et al, 2005; Hamanishi et al, 2007; Clarke et al, 2009;
Leffers et al, 2009). In contrast, the presence of the CD4-positive
regulatory subtype of T lymphocytes (Treg; CD4þCD25þ
FoxP3þ) seems to reduce tumour-specific immunity and results
in poorer survival of patients with ovarian carcinomas (Curiel
et al, 2004). Moreover, as observed for colorectal cancers (Galon
et al, 2006), the location of TILs within the tumour mass of ovarian
carcinomas has been shown to be important for revealing
a prognostic effect (Zhang et al, 2003; Sato et al, 2005; Clarke
et al, 2009).
Several issues, however, still remained unclear, especially
whether the exact localisation of TILs does influence their
prognostic/predictive value and whether the TILs detected within
ovarian carcinomas are clonally restricted and respond to a
specific tumour-specific antigen, such as the candidate
protein Her2/neu (Peoples et al, 1995; Goodell et al, 2008; Wiech
et al, 2008). In this study, we addressed these issues in a
group of stage III ovarian carcinoma patients, further stratified
into clinically relevant sub-groups of optimally debulked or
optimally debulked and adjuvant paclitaxel/carboplatin-
treated patients.
Similar to previous studies (Zhang et al, 2003; Curiel et al, 2004;
Raspollini et al, 2005; Sato et al, 2005; Hamanishi et al, 2007;
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Intraepithelial score 3;
stromal score 3
CD8:
Intraepithelial score 3;
stromal score 3
Case 4 - CD8:
Intraepithelial score 1;
stromal score 3
Case 5 - CD8:
Intraepithelial score 1;
stromal score 3
CD4:
Intraepithelial score 1;
stromal score 3
Case 1 - CD8:
Intraepithelial score 2;
stromal score 3
Case 2 - CD8:
Intraepithelial score 3;
stromal score 1
Case 3 - CD8:
Intraepithelial score 3;
stromal score 1
Case 6 - CD8:
Intraepithelial score 1;
stromal score 2
Figure 2 Representative immunohistochemical staining of lymphocytes in ovarian carcinomas. (A) Provides representative serial sections of an ovarian
carcinoma stained for CD20, CD3, CD4 and CD8, with IHC scores given below the photographs (magnification  100). (B) Shows representative IHC
stainings of CD8-positive T lymphocytes in six cases, with high (case #1, 2, 3 (left)) and low (case #4, 5, 6 (right)) intraepithelial T-lymphocyte infiltration
(magnification  100), with the IHC score given beside the photographs. Note that two cases exhibited rarified/clonal (case #1) and polyclonal (case #4) T-
cell receptor g (TCRg) rearrangements (refer to Figure 4A).
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sTomsova ´ et al, 2008; Clarke et al, 2009; Leffers et al, 2009), we
evaluated the number and exact localisation of TILs within ovarian
carcinomas and included the entire information in statistical
analyses, without using a simplified cutoff for correlation of
‘negative’ or ‘positive’ TILs with patient survival. Particularly, we
defined ‘stromal’ TILs as those located in tumour-associated
stroma and/or in perivascular spaces, and ‘intraepithelial’ TILs as
those clearly leaving the vascular/perivascular spaces to infiltrate
into the tumour cell parenchyma. As we analysed representative
tissue specimens from the central areas of only serous stage III
ovarian carcinomas, selected by an experienced pathologist to
reflect about 60% tumour and 40% stroma content, the distribu-
tion of tumour/stroma was taken into account. Similar to the study
by Zhang et al (2003), we correlated the presence of different
numbers of stromal and intraepithelial CD20-, CD3-, CD8- and
CD4-positive TILs to clinico-pathological variables and survival in
a homogeneous group of patients. With this approach, we could
further validate that the presence of high numbers of intraepithe-
lial, but not stromal, CD3-positive T lymphocytes was associated
with an improved DFS when examining all stage III patients with
optimal debulking surgery. Furthermore, we did not find a
significant correlation between the number of CD4-positive T
lymphocytes and poor survival, as observed by the specific analysis
of the CD4þCD25þFOXP3þ Treg subset of T lymphocytes
(Curiel et al, 2004). The analysis of all CD4-positive T lymphocytes
in our study may, however, have hidden such a correlation,
especially as CD4 staining alone rather detects the large majority of
CD4-positive helper T cells than the minority of Tregs. More
importantly, we confirmed and extended previous studies on the
role of CD8-positive TILs (Sato et al, 2005; Hamanishi et al, 2007;
Clarke et al, 2009; Leffers et al, 2009). The presence of high
numbers of intraepithelial, but not stromal, CD8-positive
T lymphocytes was of uni- and multivariate prognostic benefit
for stage III ovarian cancer patients, especially in the large sub-
group of patients receiving adjuvant paclitaxel/carboplatin
therapy. Interestingly, Tsuda et al, 2007 showed that Taxol stimu-
lates the immunogenic potential of CD8-positive T cells in vitro,a n
effect that may be further exploited in current therapeutic studies
(Disis et al, 2002).
In continuation, we tested the hypothesis that the intraepithelial
presence and persistence of T lymphocytes is mediated by the
recognition of (a specific) tumour-cell-specific antigen and clonal
expansion of (CD8 positive) TILs. Indeed, we showed that
lymphocytes infiltrating stage III ovarian carcinomas are shifted
to rarified or clonal TCRg gene rearrangements, an indication of
the expansion of individual T-cell clones, as can be also observed
for T-cell malignancies (van Dongen et al, 2003). Clonal restriction
occurred for TCR Vg1-8 or Vg10 chains in 6 out of 93 (6.5%) and
for Vg9o rV g11 chains in 9 out of 93 (9.7%) cases. Our data extend
and specify previous findings by Raspollini et al (2005), who
described positive PCR products for TCR Vg gene rearrangements
in 31.3% of serous ovarian carcinomas, without stratifying poly-,
oligo- or monoclonal TCRg gene rearrangements. Thus, the latter
study showed that the mere presence of TCRg gene rearrange-
ments, that is, the detection of PCR products, correlated to DFS,
which was explained to be because of the presence of T cells
expressing TCRgd proteins. However, as TCR b, d, g gene
rearrangements occur in all T cells, but are not all productive for
protein expression, DNA-based TCRg PCR analysis merely
provides information regarding the clonality of lymphocytes.
Our study now provides further insights into this issue and shows
that the presence of T cells with rarified and/or clonal TCRg gene
rearrangements may have a prognostic benefit, suggesting a
targeted immune response against ovarian carcinomas.
Nevertheless, as restricted usage of TCR Vg-Jg gene rearrange-
ments may also occur in normal individuals (Kohsaka et al,
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Figure 3 : Correlation of CD3- and CD8-positive T-lymphocyte infiltration of stage III ovarian carcinomas with clinical follow-up. The panels pro-
vide results of Kaplan–Meier analyses for overall survival with respect to intraepithelial (A and B) and stromal (C and D) CD8-positive T lymphocytes in
stage III patients with optimal debulking (A and C), as well as for stage III patients with optimal debulking and adjuvant paclitaxel/carboplatin chemotherapy
(B and D). Significant correlation to improved overall survival was only seen for increasing numbers of intraepithelial CD8-positive T lymphocytes (A and B;
refer also to main text). Coding: red lines¼IHC score 0 (no tumour-infiltrating lymphocytes (TILs)), blue lines¼IHC score 1 (o5 TILs) and green
lines¼IHC scores 2þ3( 45 TILs).
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s1993) and as TCRb gene rearrangements (Peoples et al, 1993),
which may even further support the readout of clonality analysis
(van Dongen et al, 2003), were not studied here, the results should
be interpreted carefully. In fact, the observed ‘clonal’ restriction of
TCRg gene rearrangements may either point towards infiltration of
ovarian carcinomas by one or few ab T cells with restricted TCRg
gene rearrangements, or by one or few gd T cells. In our study, the
infiltration of CD8-positive lymphocytes was of prognostic benefit.
As CD8 expression is not observed in classical gd T cells, our
results suggest that the presence of clonal CD8-positive ab
T cells may be primarily involved in a possible anti-tumoural
immune response in ovarian carcinomas. Our data encourage
further advanced studies on the nature of TIL clonality in
ovarian carcinomas, for example, also including complementary
determining region (CDR3) spectratyping of (single) microdis-
sected TILs and reconstitution of TCR chains (Hofbauer et al,
2003; Seitz et al, 2006).
In view of the potential clonal restriction of CD8-positive
T lymphocytes actively counteracting the tumour and its progres-
sion, we investigated whether the tumour-cell-specific expression
of Her2/neu protein in ovarian carcinomas may represent a
candidate target antigen of TILs, as suggested for breast cancer
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Figure 4 Analysis of T-cell receptor g (TCRg) gene rearrangements and association with survival. (A) Provides electropherogram traces of the PCR-based
TCRg gene rearrangement analysis (Materials and Methods) (van Dongen et al, 2003) for Vg1-8,10 (left) and Vg9,11 (right) in four ovarian carcinomas (cases
1, 4, 7 and 8; cases 1 and 4 are the same as in Figure 2B) and two non-neoplastic ovaries (cases 9 and 10). Cases 1 and 7 show polyclonal TCRg gene
rearrangements for Vg1-8,10 (left) and rarified/clonal TCRVg gene rearrangements for Vg9,11 (right, black arrows). Cases 8 and 4 show polyclonal TCRg
gene rearrangements for Vg1-8,10 (left) and oligoclonal/rarified TCRVg gene rearrangements for Vg9,11 (right, black arrowheads). The non-neoplastic
ovaries (cases 9 and 10) show polyclonal/oligoclonal TCRg gene rearrangements. The score for intraepithelial CD3- and CD8-positive T-cell infiltration of
each case is given beside the corresponding graphs. In the eletropherogram traces, the top x axis indicates the size range of PCR products in base pairs and
the y axis indicates the intensity of the PCR product. Blue lines/peaks represent labelled, TCRg-specific PCR products and red lines/peaks represent the
standard size marker. (B) Provides the results of Kaplan–Meier analyses for disease-free (left) and overall (right) survival of all cases with polyclonal (red line)
or rarified/clonal (blue line) TCRg gene rearrangements. Note the trend towards early improved disease-free survival for cases with rarified/clonal TCRg
gene rearrangements.
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s(Peoples et al, 1995; Goodell et al, 2008; Wiech et al, 2008) and as
shown in a murine model of ovarian cancer (Yang et al, 2007).
However, the correlation of Her2/neu protein expression to the
presence of TILs and TCRg gene rearrangements in our group of
ovarian carcinomas revealed that this is not the case, suggesting
that other tumour antigens may be more promising candidate
target antigens. Indeed, Milne et al (2008) have proposed NY-ESO-
1, a 22kDa protein encoded on chromosome Xq28 and belonging
to the so-called ‘cancer-testis antigen’, as the target antigen of TILs
in ovarian carcinomas. Clearly, further detailed studies are needed
to clarify the role of CD8-positive T cells in ovarian carcinoma and
their role in a possible anti-tumoural response in situ.
In summary, our study provides evidence that intraepithelial
infiltration of ovarian carcinomas by CD8-positive T lymphocytes
is prognostic for improved survival in optimally debulked, stage III
ovarian cancer patients, most significantly also for those with
the option of adjuvant paclitaxel/carboplatin therapy. Persistence
of these T lymphocytes within the tumour parenchyma, poten-
tially reflecting a T lymphocyte-triggered anti-tumoural immune
response, is essential for the beneficial prognostic effect. This
may be further exploited for supportive and/or novel immuno-
therapy.
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